文献速递其他结缔组织病

硬皮病临床试验联盟系统性硬化症心脏受累分类标准

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

硬皮病临床试验联盟心脏工作组通过国际跨学科共识和离散选择实验,制定了系统性硬化症心脏受累(SHI)分类标准,含23个项目,在独立队列(n=168)中验证,评分≥11分诊断SHI的敏感性78%、特异性96%,曲线下面积0.87(0.80-0.93)。

要点

  • SCTC SHI分类标准含23个项目,涵盖心脏纤维化、炎症、心律失常和小血管病变。
  • 评分≥11分诊断SHI敏感性78%、特异性96%,曲线下面积0.87(0.80-0.93)。
  • 该阈值正确识别>90%的SHI病例,无单一项目为SHI特征性表现。

核心结论

  • 新制定的SCTC SHI分类标准对系统性硬化症心脏受累具有高敏感性和特异性。

研究设计与样本

  • 国际跨学科工作组采用共识方法和现有文献制定暂定项目,通过持续共识练习和离散选择实验精简项目并推导权重。
  • 在独立队列(n=168)中测试分类标准的敏感性和特异性,该队列包含SHI病例和非SSc心脏病对照。

主要发现

  • 最终分类标准包含23个项目,测量心脏纤维化、炎症、心律失常和小血管病变。
  • 无单一项目对SHI具有特征性,诊断需多个组织病理学、影像学、血清学和影像学领域异常同时存在。
  • 分类标准评分≥11分识别SHI的敏感性为78%、特异性为96%,曲线下面积为0.87(0.80-0.93)。
  • 该阈值正确识别>90%的SHI病例。

关键数值与推荐

  • 工作组同意SCTC SHI分类标准应识别SSc对心脏的直接效应,并排除其他SSc表现或心脏合并症的并发症。
  • 分类标准评分≥11分用于识别SHI,敏感性78%、特异性96%,曲线下面积0.87(0.80-0.93)。

临床怎么用

  • 应用该分类标准可在研究中对SHI患者进行标准化分类,促进对该疾病表现的未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Systemic sclerosis-associated heart involvement (SHI) is an enigmatic disease manifestation associated with high mortality. The Scleroderma Clinical Trials Consortium (SCTC) Cardiac Working Group developed SHI classification criteria to enable systematic investigation of this condition. METHODS: An international, interdisciplinary working group was assembled. Using consensus methods and existing literature, provisional SHI classification criteria items were developed. Continuous consensus exercises and a discrete choice experiment were performed to reduce items and derive individual item weights. The sensitivity and specificity of the classification criteria were tested in an independent cohort (n = 168) of SHI (cases) and non-SSc heart disease (controls). RESULTS: The working group agreed that the SCTC SHI Classification Criteria should identify the direct effects of SSc on the heart and exclude the complications of other SSc manifestations or cardiac comorbidities. The final classification criteria include 23 items measuring cardiac fibrosis, inflammation, arrhythmias and small vessel vasculopathy. No single item is pathognomonic for SHI, with a requirement for the presence of abnormalities across multiple histopathological, imaging, serological, and imaging domains to be present to secure a diagnosis. A classification criteria score of ≥11 identified SHI with a sensitivity of 78% and specificity of 96%, with an area under the curve of 0.87 (0.80-0.93). This threshold correctly identified >90% of cases of SHI. CONCLUSION: The newly derived SCTC SHI Classification Criteria have high sensitivity and specificity for SHI. Application of these criteria will enable standardized classification of patients in studies to facilitate future investigation of this important disease manifestation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ross L, Burns AT, La Gerche A, et al. Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement. Rheumatology (Oxford). 2026. PMID: 41758916. doi:10.1093/rheumatology/keag109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。